The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

NCT02558231 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Macitentan
DRUG: Tadalafil
DRUG: Selexipag

Sponsor

Actelion